← Leaderboards
John Rose
Yale University
$16,253,868
Attributed
$16,832,176
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–16$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$16,832,176 · 11
By mechanism
R01$9,549,338 · 4
R37$3,084,887 · 1
R56$2,094,911 · 2
U54$1,309,247 · 1
R21$457,875 · 1
P20$335,918 · 2
Top collaborators
- John H Eldridge1 shared
Most similar at Yale University
Same institution · by research overlap
- Anthony N Van Den Pol$25,732,423
- Murat Gunel$29,485,998
- Joann B Sweasy$35,063,022
Others in their field
Top investigators on “Neutralizing Antibody”
- Barton F Haynes · Duke University$361,488,167
- Dennis R. Burton · Scripps Research Institute$328,455,703
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$262,392,049
- Lawrence Corey · Fred Hutchinson Cancer Center$257,355,255
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$139,509,763
Research focus
Neutralizing AntibodyBaseVectorVector VaccineAids VaccinesMacaca MulattaResponseAttenuatedVesicular Stomatitis Indiana VirusAntibodiesNonhuman PrimateVector-Based VaccineProteinsImmune ResponseVirusVaccinesRecombinantsHiv VaccineCellular ImmunityAntigensLifeGenesRecombinant VirusAntibody Formation
Grant awards (40)
TESTING A NOVEL APPROACH TOWARD A MULTIVALENT CHIKUNGUNYA/DENGUE VACCINE$249,750
R21 · FY2016 · AI · contact PI
TESTING A NOVEL APPROACH TOWARD A MULTIVALENT CHIKUNGUNYA/DENGUE VACCINE$208,125
R21 · FY2015 · AI · contact PI
Development of Chimeric Vesiculo/Alphaviruses as an Alphavirus Vaccine$1,156,616
R56 · FY2013 · AI · contact PI
Development of Novel Vaccines for High Priority Pathogens$411,995
U54 · FY2013 · AI · contact PI
Development of Novel Vaccines for High Priority Pathogens$410,626
U54 · FY2012 · AI · contact PI
Novel vaccines for broad protection against avian influenza$405,516
R01 · FY2012 · AI · contact PI
Development of VSV/HIV Recombinants as HIV Vaccines$324,413
R37 · FY2012 · AI · contact PI
Immune Responses to VSV/HIV/SIV Hybrids in Macaques$810,993
R56 · FY2011 · AI · contact PI
Development of Novel Vaccines for High Priority Pathogens$486,626
U54 · FY2011 · AI · contact PI
Novel vaccines for broad protection against avian influenza$405,516
R01 · FY2011 · AI · contact PI
Development of VSV/HIV Recombinants as HIV Vaccines$324,413
R37 · FY2011 · AI · contact PI
Immune responses to VSV/HIV/SIV Hybrids in Macaques$706,501
R01 · FY2010 · AI · contact PI
Novel vaccines for broad protection against avian influenza$409,613
R01 · FY2010 · AI · contact PI
Development of VSV/HIV Recombinants as HIV Vaccines$327,690
R37 · FY2010 · AI · contact PI
Immune responses to VSV/HIV/SIV Hybrids in Macaques$710,367
R01 · FY2009 · AI · contact PI
Novel vaccines for broad protection against avian influenza$413,750
R01 · FY2009 · AI · contact PI
Development of VSV/HIV Recombinants as HIV Vaccines$331,000
R37 · FY2009 · AI · contact PI
Immune responses to VSV/HIV/SIV Hybrids in Macaques$545,157
R01 · FY2008 · AI · contact PI
Development of VSV/HIV Recombinants as HIV Vaccines$330,500
R37 · FY2008 · AI · contact PI
Immune Responses to VSV/HIV/SIV Hybrids in Macaques$127,302
R56 · FY2008 · AI · contact PI
Immune Responses to VSV/HIV/SIV Hybrids in Macaques$541,248
R01 · FY2007 · AI · contact PI
Development of VSV/HIV Recombinants as HIV Vaccines$310,055
R37 · FY2007 · AI · contact PI
INBRE: BIOINFORMATICS CORE$165,199
P20 · FY2007 · RR · contact PI
Immune Responses to VSV/HIV/SIV Hybrids in Macaques$544,302
R01 · FY2006 · AI · contact PI
Development of VSV/HIV Recombinants as HIV Vaccines$319,316
R37 · FY2006 · AI · contact PI
INBRE: BIOINFORMATICS CORE$170,719
P20 · FY2006 · RR · contact PI
Immune Responses to VSV/HIV/SIV Hybrids in Macaques$573,574
R01 · FY2005 · AI
Development of VSV/HIV Recombinants as HIV Vaccines$327,000
R37 · FY2005 · AI
Immune Responses to VSV/HIV/SIV Hybrids in Macaques$623,174
R01 · FY2004 · AI
Development of VSV/HIV Recombinants as HIV Vaccines$327,000
R37 · FY2004 · AI
Immune Responses to VSV/HIV/SIV Hybrids in Macaques$637,975
R01 · FY2003 · AI
Development of VSV/HIV Recombinants as HIV Vaccines$163,500
R37 · FY2003 · AI
IMMUNE RESPONSES TO VSV/HIV/SIV HYBRIDS IN MACAQUES$490,129
R01 · FY2002 · AI
DEVELOPMENT OF VSV/HIV RECOMBINANTS AS HIV VACCINES$247,268
R01 · FY2002 · AI
IMMUNE RESPONSES TO VSV/HIV/SIV HYBRIDS IN MACAQUES$501,584
R01 · FY2001 · AI
ASSEMBLY AND APPLICATION OF RECOMBINANT RHABDOVIRUSES$429,743
R01 · FY2001 · AI
DEVELOPMENT OF VSV/HIV RECOMBINANTS AS HIV VACCINES$241,265
R01 · FY2001 · AI
IMMUNE RESPONSES TO VSV/HIV/SIV HYBRIDS IN MACAQUES$489,075
R01 · FY2000 · AI
ASSEMBLY AND APPLICATION OF RECOMBINANT RHABDOVIRUSES$421,298
R01 · FY2000 · AI
DEVELOPMENT OF VSV/HIV RECOMBINANTS AS HIV VACCINES$212,283
R01 · FY2000 · AI